Monoclonal antibodies block the bromelain-mediated release of human placental alkaline phosphatase from cultured cancer cells.
Certain monoclonal antibodies (mAbs) to human placental alkaline phosphatase (PLAP) block bromelain cleavage of a 2-kDa segment from each of the two polypeptide chains of PLAP. These mAbs also prevent the release of PLAP from cultured cancer cell surfaces by bromelain. Such proteolysis-blocking mAbs serve as tools to specifically modify the molecular topography of cell surfaces by protease treatment.
D000469:Alkaline Phosphatase / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000502:physiology*; D001963:Bromelains / Q000378:metabolism / Q000494:pharmacology*; D002462:Cell Membrane / Q000201:enzymology; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006367:HeLa Cells / Q000201:enzymology; D006801:Humans; D010920:Placenta / Q000201:enzymology*; D011247:Pregnancy; D014357:Trypsin / Q000378:metabolism
D000911:Antibodies, Monoclonal; D001963:Bromelains; D000469:Alkaline Phosphatase; D014357:Trypsin